Skip to main content
. 2019 May 1;21(6):582–590. doi: 10.1016/j.neo.2019.03.014

Table 3.

Patient Characteristics According to Ras Mutation or Wild-Type

Ras Mutant
N = 14
Non-Ras Mutant
N = 24
P Value
Median age (years) 58.5 39.5 .220
Range (28-68) (25-76)
Mean age 53.7 47.1
FIGO stage
I 3 (21.4%) 1 (4.2%) .105
II - -
III 7 (50%) 21 (87.5%)
IV 4 (28.6%) 2 (8.3%)
Surgery
Primary debulking 7 (50%) 18 (75%) .163
Interval debulking 7 (50%) 6 (25%)
Residual tumor
R0 11 (78.6%) 22 (91.7%) .337
R > 1 3 (21.4%) 2 (8.3%)
R0-1 - -
Association of borderline component 6 (42.9%) 12 (50%) .745
Initial systemic treatment
Platinum-based chemo 13 (92.9%) 24 (100%) .368
Hormonal treatment 1 (7.1%) - -
Bilateral 9 (64.3%) 19 (79.2%) .217
Unilateral 5 (35.7%) 3 (12.5%)
Unknown - 2 (8.3%)
Lymph node involvement
Yes 6 (42.9%) 9 (37.5%)
No 8 (57.1%) 15 (62.5%)
Ascites
Yes 6 (42.9%) 4 (16.7%) 1.000
No 8 (57.1%) 19 (79.2%)
Unknown - 1 (4.2%)